Omeros Corporation

Seattle,  WA 
United States

Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. In addition to its commercial product OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%, Omeros has multiple late stage clinical development programs focused on complement-mediated disorders, including a Phase 3 study (ARTEMIS) for IgA nephropathy.